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Friedreich’s ataxia (FRDA) is the most common hereditary ataxia, affecting ∼3 in 100 000 individuals in
Caucasian populations. It is caused by intronic GAA repeat expansions that hinder the expression of the
FXN gene, resulting in defective levels of the mitochondrial protein frataxin. Sensory neurons in dorsal
root ganglia (DRG) are particularly damaged by frataxin deficiency. There is no specific therapy for FRDA.
Here, we show that frataxin levels can be upregulated by interferon gamma (IFNg) in a variety of cell
types, including primary cells derived from FRDA patients. IFNg appears to act largely through a transcrip-
tional mechanism on the FXN gene. Importantly, in vivo treatment with IFNg increases frataxin expression
in DRG neurons, prevents their pathological changes and ameliorates the sensorimotor performance in
FRDA mice. These results disclose new roles for IFNg in cellular metabolism and have direct implications
for the treatment of FRDA.
INTRODUCTION
Friedreich’s ataxia (FRDA) is a devastating orphan disease.
Symptoms usually appear late in the first decade or early in
the second decade of life, and include features of both periph-
eral and cerebellar ataxia. Cardiac involvement is very fre-
quent and premature death is often caused by cardiac
insufficiency due to dilated cardiomyopathy. Approximately
10% of patients also develop diabetes mellitus (1).
FRDA is caused by defective frataxin expression. Frataxin
is a mitochondrial protein, synthesized as a 210-amino acid
precursor that is proteolytically processed into a 130-amino
acid mature polypeptide (2,3). Frataxin binds iron and it is
involved in the assembly of iron-sulfur clusters (ISC) (4,5),
prosthetic groups incorporated into several key metabolic
enzymes (6). Frataxin-defective cells in fact have reduced ac-
tivity of ISC-containing enzymes, such as aconitase and suc-
cinate dehydrogenase, a general imbalance in intracellular
iron distribution and increased sensitivity to oxidative stress.
The cells mostly affected by frataxin reduction are the large
sensory neurons of dorsal root ganglia (DRG) (7).
There is currently no specific therapy to prevent the progres-
sion of the disease (8). Here, we show that frataxin can be
upregulated by interferon gamma (IFNg), a cytokine involved
in multiple aspects of iron metabolism and the immune re-
sponse (9). Most importantly, in vivo treatment with IFNg
increases frataxin levels in DRG neurons and substantially
prevents DRG neuronal degeneration and neurological dys-
function in FRDA mice.
RESULTS
During the course of a proteomic screening for proteins differ-
entially expressed in cells derived from FRDA patients, a seren-
dipitous observation suggested that IFNg might upregulate
frataxin. Different IFNg-responsive cell lines were then
exposed to recombinant IFNg and frataxin accumulation was
quantitated after 24 h by sodium dodecyl sulfate–polyacrylamide
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gel electrophoresis (SDS–PAGE) and immunoblot analysis. As
shown in Figure 1, IFNg induces the accumulation of frataxin in
human cervical carcinoma HeLa cells (Fig. 1A) and in the
monocytic leukemia cell line U937 (Fig. 1B) in a dose-
dependent manner. Similarly, IFNg can promote frataxin
expression in the human glioblastoma cell line U118
(Fig. 1C). To verify that IFNg could induce frataxin accumula-
tion in non-transformed cells, resting peripheral blood mono-
nuclear cells (PBMC) from normal individuals were exposed
to IFNg and frataxin accumulation was quantitated by SDS–
PAGE and immunoblot analysis. Figure 1D shows that IFNg
can induce frataxin accumulation in resting PBMC in a dose-
dependent manner. Together, these data indicate that IFNg is
able to upregulate frataxin levels in a variety of cell types.
We then tested whether IFNg can upregulate frataxin in
cells derived from FRDA patients. FRDA-derived GM03816
fibroblasts were exposed for 24 h to different doses of IFNg,
and then frataxin was quantitated by SDS–PAGE and immu-
noblot analysis. Figure 2A shows that IFNg can induce the
upregulation of frataxin in frataxin-defective fibroblasts, in a
dose-dependent manner. To verify that IFNg could be effect-
ive on primary FRDA cells, freshly isolated PBMC from
several FRDA patients were exposed to different doses of
IFNg for 24 h. Frataxin was then quantitated by SDS–
PAGE and immunoblot analysis. As shown in Figure 2B,
PBMC isolated from a FRDA patient, and treated for 24 h
with IFNg, exhibit significantly increased levels of frataxin
expression, in a dose-dependent manner. Comparison with
the levels of frataxin present in a healthy control (a brother
of the patient) indicates that IFNg induces a substantial recov-
ery of frataxin levels. PBMC isolated from 9 out of 10 FRDA
patients tested gave similar results.
To gain insight into the mechanism of frataxin upregulation,
we investigated whether IFNg treatment modulated frataxin
mRNA levels. Quantitative RT–PCR analysis showed that a
significant increase in frataxin mRNA can be detected in
FRDA fibroblasts as early as 1 h after exposure to IFNg,
with peak accumulation at 2 h and return to baseline levels
after 4 h (Fig. 2C). Moreover, pre-treatment with actinomycin
D completely prevented IFNg-induced frataxin mRNA accu-
mulation (Fig. 2D). The mRNA accumulation of a control
IFNg-inducible gene, the immunoproteasome component
PA28 alpha subunit (10), was similarly prevented. These
results strongly suggest that IFNg induces frataxin accumula-
tion in FRDA cells largely by increasing frataxin transcripts,
although additional mechanisms such as mRNA stabilization
or protein stabilization cannot be excluded.
To investigate whether IFNg could be effective in vivo, we
utilized the YG8R FRDA mouse model (11,12). This model
contains a human genomic FXN transgene, driven by the
human FXN promoter, together with expanded GAA repeats
within intron 1 of the FXN gene. In addition, the FXN trans-
genic mice have been crossed with frataxin knockout mice
to ensure that the resultant YG8R FRDA mice only express
human transgenic frataxin and not any endogenous mouse fra-
taxin. Thirteen FRDA mice were treated with subcutaneous
injections of 40 mg/kg IFNg [in phosphate buffered saline
(PBS)], three times/week from 8 weeks of the age for 14
weeks, while 13 FRDA mice of the same age were given
PBS, using the same schedule. Every 2 weeks, motor coordin-
ation and locomotor activity were assessed. As shown in
Figure 3, FRDA mice treated with IFNg displayed significant-
ly enhanced locomotor activity, as measured by ambulatory
distance (Fig. 3A), average velocity (Fig. 3B) and vertical
counts (Fig. 3C), compared with PBS-treated FRDA mice.
Perhaps more importantly, motor coordination, as measured
by rotarod performance, improved dramatically in IFNg-
treated mice after 10 weeks of treatment compared with
Figure 1. IFNg induces frataxin accumulation in multiple cell types. HeLa
cells (A), U937 cells (B), U118 cells (C) and PBMC isolated from healthy
donors (D) were cultured for 24 h in the presence of the indicated concentra-
tions of IFNg, and then whole cell lysates were analyzed by SDS–PAGE and
blotted with anti-frataxin and anti-actin mAbs. Representative blots are shown,
three to six independent experiments for each cell type were performed.
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PBS-treated mice (Fig. 3D). Better performances in locomotor
activity and motor coordination in IFNg-treated mice occurred
independently of body weight changes (Fig. 3E).
We then analyzed the expression of human frataxin, as well
as the pathological features, in DRG neurons from FRDA
mice, following IFNg treatment (40 mg/kg IFNg three times/
week for 14 weeks) or PBS treatment. Higher levels of
human frataxin expression can be detected in DRG tissue
samples from IFNg-treated FRDA mice, compared with
PBS-treated FRDA mice, as detected by immunohistochemis-
try (Fig. 4A–D). Accordingly, the accumulation of mature
human frataxin in DRG from IFNg-treated FRDA mice, com-
pared with PBS-treated FRDA mice can also be detected by
SDS–PAGE/western blot analysis, both in female and male
mice groups (Fig. 4E and F). Most importantly, DRG degen-
eration is prevented by in vivo IFNg treatment. HE staining
of DRG tissue collected from FRDA mice that received PBS
shows several neurons with typical vacuolar degeneration
(Fig. 5A, arrows), as previously described (11,13). These fea-
tures were virtually absent in FRDA mice treated with IFNg
(Fig. 5B). Quantitation and statistics of vacuolated DRG
neurons in PBS and IFNg-treated FRDA mice is shown in
Figure 5C.
DISCUSSION
Our data indicate that exposure to IFNg induces the upregula-
tion of cellular frataxin. Innate immunity actively controls iron
metabolism during microbial infections (14). Within hours
from the detection of bacterial proliferation, a massive redistri-
bution of bioavailable iron between the extracellular fluids and
the cells of the reticulo-endothelial system, is orchestrated by
inflammatory cytokines, primarily by IFNg (15). This process,
highly conserved in evolution, is mainly aimed at restricting
iron access to invading pathogens, while preserving iron avail-
ability to the benefit of the host defense (16). In particular,
IFNg appears to extensively control iron distribution and
availability by directly modulating the expression of a
number of players in iron metabolism, including ferritin
(17), the transferrin receptor (17,18), the iron exporter ferro-
portin (19), its peptide ligand hepcidin (20), IRP1 (21) and
the iron symporter NRAMP1 (22). In general, extracellular
iron is reduced, and iron is sequestered within cells. This scen-
ario might justify a requirement for additional frataxin as a
regulator of iron redistribution (23), particularly controlling
the access of extra iron to the mitochondrial ISC machinery,
in keeping with a recently proposed hypothesis (5).
Figure 2. IFNg induces frataxin accumulation in FRDA cells. FRDA fibroblasts (GM03816 cells) (A) and PBMC freshly isolated from an FRDA patient (B)
were cultured for 24 h in the presence of the indicated concentrations of IFNg, and then whole cell lysates were analyzed by SDS–PAGE and blotted with
anti-frataxin and anti-actin mAbs. The amount of frataxin present in the PBMC of a healthy sibling of the patient is also shown for comparison (HC). Nine
out of 10 different FRDA patients (6 males and 4 females, GAA triplets range 350–915, age range 14–56) tested gave similar results. (C) IFNg induces ac-
cumulation of frataxin mRNA in FRDA cells. FRDA fibroblasts were cultured for the indicated times in the presence of 500 ng/ml of IFNg, and then frataxin
mRNA was quantitated by RT–PCR. The means+1 SD from three independent experiments is shown. The increase in frataxin mRNA in IFNg-treated cells,
versus control-treated cells, was significant at 1 h (∗∗P, 0.001) and at 2 h (∗P, 0.05). (D). Actinomycin D blocks IFNg-induced frataxin mRNA accumulation
in FRDA cells. FRDA fibroblasts were pre-treated for 30 min with 5 mg/ml actinomycin D, cultured for 2 h in the presence of 500 ng/ml of IFNg and then
frataxin mRNA (black columns) and PA28alpha mRNA (grey columns) were quantitated by RT–PCR. The means+1SD from two independent experiments
is shown.
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IFNg also triggers a variety of biological effects aimed at
regulating the immune response and counteract infections
(24). By directly inducing components of the reduced nico-
tinamide adenine dinucleotide phosphate oxidase complex
and iNOS, IFNg controls the generation of reactive oxygen
species and nitric oxides (NO, including intermediates and
derivatives), both required for optimal antimicrobial
responses. However, NO are known to cause nitrosylation
and consequent disruption of prosthetic ISC (25), suppressing
the activity of ISC-containing enzymes, such as aconitase. The
upregulation of frataxin might therefore be required to com-
pensate and/or prevent possible ISC disruption, and conse-
quent loss of function of ISC-containing proteins, in cells
exposed to IFNg. Relevant to this, we observed that the
IFNg-induced upregulation of frataxin in FRDA cells results
also in a strong upregulation of aconitase activity (unpublished
data).
Most importantly, our data show that FRDA mice improve
both locomotor activity and motor coordination, when treated
with IFNg, and that this is paralleled by both frataxin upregu-
lation and neuronal preservation in DRG. IFNg is usually pro-
duced by lymphocytes, but, intriguingly, DRG neurons can
both release and respond to IFNg in an autocrine/paracrine
fashion (26). It is therefore possible that the interruption of
an IFNg-dependent feed-forward trophic mechanism (27), sus-
taining frataxin levels, might contribute to the exquisite sensi-
tivity of DRG to frataxin deficiency. Exogenously
administered IFNg might reach relevant neurons in disar-
ranged FRDA DRG (7) to rescue frataxin levels and grant
cell survival. While the specific target tissues for IFNg in
FRDA remain to be further characterized, these data are im-
mediately relevant to the search for effective treatment of
FRDA. No approved cure is currently available to FRDA
patients (8). Current therapeutic approaches are based on the
use of anti-oxidants or iron chelators, with controversial
results. Other strategies are in earlier clinical phases or pre-
clinical stage (13,28). Recombinant IFNg is approved for
therapeutic use (29). Our data warrant an evaluation of IFNg
as a treatment for FRDA.
MATERIALS AND METHODS
Cell cultures
HeLa (human cervical carcinoma), U937 (monocytic leuke-
mia) and U118 (human glioblastoma) cell lines were obtained
from the European cell culture collection. Human fibroblasts
derived from a FRDA patient (GM03816) were obtained
from the National Institute of General Medical Sciences
(NIGMS), Human Genetic Cell Repository. Recombinant
human and murine IFNg were from Peprotech.
Immunoblotting
Total cell extracts were prepared in ice-cold radio immuno
precipitation assay lysis buffer. Proteins were separated on
12% SDS–PAGE, electroblotted on Protran Nitrocellulose
Membranes (Whatman) and analyzed by ECL detection (GE
Healthcare Life Sciences) with mAb anti-frataxin
(MAB-10876 Immunological Sciences), mAb anti-actin
(Sigma), mAb anti-PA28alpha (ENZO Lifesciences) and
pAb anti-VDAC (Abcam).
Figure 3. In vivo IFNg treatment improves locomotor and motor coordination
performances in FRDA mice. Two groups of 13 eight-week-old FRDA mice
were used, one group injected subcutaneously with 40 mg/kg IFNg, three
times/week for 14 weeks and the other with PBS. Every 2 weeks, functional
evaluation of locomotor and coordination activity was performed. Mean
values for each functional parameter measured from all 13 FRDA mice of
each group are shown at the indicated time points. Both locomotor parameters,
such as ambulatory distance (A, P, 0.01), average velocity (B, P , 0.01),
vertical counts (C, P , 0.001) and coordination parameters such as rotarod
performance (D, P, 0.001) gave significantly different results between the
two groups. Body weight was also measured at every time point (E).
Squares: IFNg-treated animals, triangles: PBS-treated animals.
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Quantitative RT–PCR
Total RNA (500 ng) isolated from FRDA fibroblasts was
extracted using TRI-zol reagent (Invitrogen) and cDNA was
then prepared by using SuperScript VILO cDNA synthesis
kit (Invitrogen). Levels of human FXN mRNA expression
were assessed by quantitative RT–PCR using an ABI Prism
7000 sequencer and SYBR Green (Applied Biosystems) with
the following primers: RTFXNFWD 5′-CATACACGTTTGA
GGACTATGATGTCT-3′ and RTFXNREV 5′-TTCGGCGTC
TGCTTGTTGATC-3′ (Invitrogen) and QuantiTect Primer
Assay (200) (QT00095431) (Qiagen) for actin primers as
housekeeping gene. Quantitative real-time PCR analysis was
carried out using the 2(-Delta Delta C(T)) method. Statistical
analysis was performed using a Student’s t-test. In some
experiments, FRDA fibroblasts were pre-treated for 30′ with
5 mg/ml of actinomycin D (Sigma Aldrich), and then treated
with 500 ng/ml of IFNg for 2 h. Levels of human
PA28alpha mRNA expression were assessed with the follow-
ing primers: RTPA28alphaFWD 5′-TCCTTCTGCAGCGCTT
GAA-3′ and RTPA28alphaREV 5′-CTCAATCCGAGGTATC
TGCAGC-3′.
Animal procedures and behavioral assessments
The YG8R mice were established by cross breeding YG8
human genomic YAC transgenic mice that contain the
entire FXN gene and expanded GAA repeats, with heterozy-
gous Fxn-knockout mice (12). Thirteen YG8R mice starting
Figure 4. In vivo IFNg treatment upregulates human frataxin in DRG of FRDA mice. Immunohistochemistry of DRG tissue from PBS-treated FRDA mice
(A and C) and IFNg-treated FRDA mice (B and D), after 14 weeks of treatment. Immunostaining (see Materials and Methods) was performed in the presence
(A and B) or absence (C and D) of anti-frataxin mAb, followed by anti-mouse IgG secondary antibody treatment and DAB staining. All four panels were counter-
stained with hematoxylin. (E). SDS–PAGE analysis of cell extracts from pooled DRG neurons from male (M, n ¼ 3) and female (F, n ¼ 2) FRDA mice, treated
with either PBS or 40 mg/kg IFNg three times/week for 14 weeks. Blots were analyzed for the mitochondrial protein VDAC (as negative control), for the
IFNg-inducible PA28alpha (as positive control), and for human frataxin. (F). Densitometric analysis of the results shown in (E). Data are presented as %
fold induction of frataxin accumulation in DRG neurons of IFNg-treated FRDA mice compared with frataxin levels in DRG neurons of PBS-treated FRDA mice.
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at 8 weeks of age were given subcutaneous injection of
40 mg/kg murine IFNg (PeproTech) three times/week for
14 weeks. Thirteen age-matched YG8R mice were given
PBS as control, using the same schedule. Tissues were col-
lected 4 h after the last injection. Rotarod performances
were assessed using an Ugo Basile 7650 accelerating
rotarod treadmill (12). Ambulatory distance, average velocity
and vertical counts (mouse lifts up) were measured over
1 min periods in the dark and repeated four times for each
mouse using a beam-breaker activity monitor (Medical
Devices, Inc.). The mean performance for each group of
mice was calculated at the indicated times. Data were ana-
lyzed by two-way analysis of variance.
DRG histology and immunohistochemistry
Histological preparations of mouse DRG were carried out by
dissection of paraformaldehyde-fixed intact lumbar vertebrae,
followed by decalcification treatment in Hillman and Lee’s
ethylenediaminetetraacetic acid, daily for 5 days. Tissues
were then embedded in paraffin wax, sectioned, deparaffined
and stained with hematoxylin/eosin. Immunostaining was per-
formed on deparaffined sections after blocking with MOM
mouse IgG (Vector Labs). Sections were incubated overnight
with anti-frataxin mAb (1G2), followed by biotinylated anti-
mouse IgG secondary antibody and an avidin-biotin complex
(Vectastain Elite) reagent, and finally colored with the DAB
substrate kit for peroxidase.
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